PATLY.AIApplication
17786717 · COMBINATION OF ANTI TIM-3 ANTIBODY MBG453 AND ANTI TGF-BETA ANTIBODY NIS793, WITH OR WITHOUT DECITABINE OR THE ANTI PD-1 ANTIBODY SPARTALIZUMAB, FOR TREATING MYELOFIBROSIS AND MYELODYSPLASTIC SYNDROME
Filed 2022-06-17 · Abandoned The official file ↗ · Art unit 1642 · Examiner Cheng Lu Typical · CPC C07K 16/22 · NOVARTIS AG · K&L Gates - Novartis
Office actions
0
first was Restriction requirement
RCEs
0
no appeal
To first action
35.4 mo
to disposition 43.1 mo
Statutes raised
·
0 actions read